title: Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
abstract: INTRODUCTION Epidermal growth factor receptor (EGFR) mutation related to tyrosine kinase inhibitors' (TKIs) responsiveness in non-small cell lung cancer (NSCLC) has become an important issue for therapeutic decision-making in NSCLC patients. MATERIAL AND METHODS Sixty-nine Caucasian NSCLC patients were screened for mutations in the tyrosine kinase (TK) domain of EGFR by direct sequencing from December 2005 to September 2010. RESULTS Activating mutations in the EGFR TK domain were found in 8 of 69 (11.6%) (7 deletions in exon 19 and one L858R mutation in exon 21). Seven of those mutations were found in adenocarcinoma and one mutation in bronchiolo-alveolar carcinoma; five of them in females (one smoker) and three of them in males (one smoker). All patients carrying activating mutations in the TK domain of EGFR were treated with TKIs. Ten patients not carrying an activating mutation in EGFR, who progressed after chemotherapy, were also treated with compassionate use of EGFR-specific TKIs (gefitinib or erlotinib). An objective response (partial response) was observed in all patients carrying an activating mutation in EGFR that received TKIs. Median overall survival for these patients has not been reached, however mean survival has been estimated at 39.5 months (95% CI, 22-57). CONCLUSIONS As previously reported, EGFR TK mutational analysis was a predictive test for response to targeted therapy with EGFR TKIs. The early identification of these patients consistently attains disease response and clearly improves outcomes.
authors.affiliation: Molecular Genetics Laboratory, Plataforma de Oncología, USP Hospital San Jaime, Torrevieja, Alicante, Spain. elena1.martinez@usphospitales.com
authors.forename: E M
authors.initials: EM
authors.lastname: Martínez-Navarro
authors.forename: J
authors.initials: J
authors.lastname: Rebollo
authors.forename: R
authors.initials: R
authors.lastname: González-Manzano
authors.forename: M
authors.initials: M
authors.lastname: Sureda
authors.forename: E
authors.initials: E
authors.lastname: Evgenyeva
authors.forename: B
authors.initials: B
authors.lastname: Valenzuela
authors.forename: F J
authors.initials: FJ
authors.lastname: Fernández
authors.forename: J
authors.initials: J
authors.lastname: Forteza
authors.forename: A
authors.initials: A
authors.lastname: Brugarolas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib
references.citation: Oncogene. 2006 Feb 23;25(8):1205-15
references.pmid: 16205628
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references.pmid: 17020982
references.citation: J Mol Signal. 2010 Jul 12;5:8
references.pmid: 20624308
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4247-53
references.pmid: 19667264
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: J Clin Oncol. 2005 Jan 1;23(1):235-7
references.pmid: 15625379
references.citation: N Engl J Med. 2009 Sep 3;361(10):958-67
references.pmid: 19692684
references.citation: PLoS Med. 2005 Jan;2(1):e17
references.pmid: 15696205
references.citation: Cancer Sci. 2006 Aug;97(8):753-9
references.pmid: 16863509
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Ann Oncol. 2005 Jul;16(7):1081-6
references.pmid: 15851406
references.citation: J Thorac Oncol. 2006 Sep;1(7):635-47
references.pmid: 17409930
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8195-203
references.pmid: 15623594
references.citation: Cancer. 2009 Apr 15;115(8):1723-33
references.pmid: 19170230
references.citation: Clin Transl Oncol. 2008 Jul;10(7):442-4
references.pmid: 18628075
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4275-83
references.pmid: 18594010
references.citation: N Engl J Med. 2010 Jun 24;362(25):2380-8
references.pmid: 20573926
references.citation: Lung Cancer. 2006 Dec;54(3):419-22
references.pmid: 17045698
references.citation: Oncologist. 2008 Dec;13(12):1276-84
references.pmid: 19060236
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073